Revenue Breakdown
Composition ()
No data
Revenue Streams
Biogen Inc (BIIB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MS product revenues-TYSABRI, accounting for 32.6% of total sales, equivalent to $827.20M. Other significant revenue streams include Spinal Muscular Atrophy-SPINRAZA and MS product revenues-Fumarate. Understanding this composition is critical for investors evaluating how BIIB navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Biogen Inc maintains a gross margin of 68.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.62%, while the net margin is 18.40%. These profitability ratios, combined with a Return on Equity (ROE) of 9.31%, provide a clear picture of how effectively BIIB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BIIB competes directly with industry leaders such as RPRX and HCM. With a market capitalization of $25.33B, it holds a leading position in the sector. When comparing efficiency, BIIB's gross margin of 68.04% stands against RPRX's 100.00% and HCM's 39.65%. Such benchmarking helps identify whether Biogen Inc is trading at a premium or discount relative to its financial performance.
